EGFR and hepatocellular carcinoma: HCC lines in the well-differentiated group proved to be more sensitive than their counterparts against a larger number of investigated drugs/agents, including several TKIs such as those targeting EGFR (erlotinib), IGF1R (linsitinib, BMS-536924, BMS-754807), or other kinases (linifanib, masitinib, imatinib).